3.02
1.65%
0.0491
After Hours:
3.02
Synaptogenix Inc stock is traded at $3.02, with a volume of 12,742.
It is up +1.65% in the last 24 hours and down -23.66% over the past month.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
See More
Previous Close:
$2.9709
Open:
$3.12
24h Volume:
12,742
Relative Volume:
0.41
Market Cap:
$4.08M
Revenue:
-
Net Income/Loss:
$-560.20K
P/E Ratio:
-2.0828
EPS:
-1.45
Net Cash Flow:
$-6.90M
1W Performance:
-2.89%
1M Performance:
-23.66%
6M Performance:
-35.57%
1Y Performance:
-72.55%
Synaptogenix Inc Stock (SNPX) Company Profile
Name
Synaptogenix Inc
Sector
Industry
Phone
(973) 242-0005
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Synaptogenix Inc Stock (SNPX) Latest News
Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com
Synaptogenix announces new preferred stock series - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com Canada
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com UK
Synaptogenix Announces $5.0 Million Financing - StockTitan
Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World
Synaptogenix extends preferred shares maturity date - Investing.com
Synaptogenix extends preferred shares maturity date - Investing.com India
Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix - The Pharma Letter
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
New collab to probe potential of fatty acid analogs in Alzheimer's - The Pharma Letter
Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix begins pre-clinical trials for SCI treatment - Investing.com
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - Lelezard
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - StockTitan
Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to “Buy” - Defense World
Synaptogenix (NASDAQ:SNPX) Trading Down 0.5% - Defense World
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
Synaptogenix Acquires 25% Stake In Cannasoul - Quantisnow
FDA grants IND authorisation for Synaptogenix's multiple sclerosis trial - Yahoo Finance
FDA grants IND authorisation for Synaptogenix's multiple sclerosis trial - Clinical Trials Arena
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com Australia
Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com Canada
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Dana Incorporated names Lisa Amend as new HR Chief By Investing.com - Investing.com South Africa
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - StockTitan
Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024TipRanks.com - TipRanks
Alzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com
Synaptogenix (NASDAQ:SNPX) Stock Price Up 1% - Defense World
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - InvestorPlace
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for ... - Investing.com India
Synaptogenix regains Nasdaq listing compliance By Investing.com - Investing.com
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report
What's Going On With Synaptogenix (SNPX) Stock?Synaptogenix (NASDAQ:SNPX) - Benzinga
Synaptogenix Inc Stock (SNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):